【摘要】 目的:探讨c-erbB-2、p53、增殖细胞核抗原(proliferating cell nuc lear antigen,PCNA)和DNA拓扑异构酶Ⅱ(DNAtopoisom eraseⅡ,TopoⅡ)及雌激素受体(estrogen receptor,ER)和孕激素受体(progesterone receptor,PR)在乳腺癌的表达和临床病理关系。方法:89例乳腺癌石蜡切片标本免疫组化EnV ision法染色。结果:c-erbB-2、p53、TopoⅡ和PCNA在乳腺癌的阳性率分别为64.04%、29.21%、55.06%和59.55%,其中c-erbB-2、PCNA在淋巴结有无转移之间表达差异有统计学意义(P<0.05),且PCNA的表达与乳腺浸润性癌的关系密切。而TopoⅡ在淋巴结转移间差异无统计学意义(P>0.05)。结论:c-erbB-2、PCNA可以作为判断乳腺癌患者预后的有效指标,TopoⅡ在乳腺癌中的表达可作为指导乳腺癌化疗的重要指标和判断乳腺癌预后的参考指标。更多还原

【Abstract】 Objective:To evaluate the clinicopathological significance of expressions of c-erbB-2,p53,proliferating cell nuclear antigen(PCNA),DNA topoisomerase Ⅱ(TopoⅡ),estrogen receptor(ER) and progesterone receptor(PR) in breast cancer.Methods:Eighty-nine cases of paraffin-embedded specimens of breast carcinoma were studied by immunohistochemical technique.Results:The positive rates of c-erbB-2,p53,TopoⅡand PCNA were 64.04%,29.21%,55.06%,and 59.55%,respectively.The expressions of c-erbB-2,PCNA were positively correlated with lymph node metastases(P<0.05),and there was the closely relationship between PCNA and invasive mammary carcinoma.But there was no relationship between TopoⅡ and 1ymph node metastases(P>0.05).Conclusions:The results suggested that c-erbB-2 and PCNA can be effective markers for estimating the prognosis of breast cancer.The expressions of TopoⅡ may be useful in predicting prognosis and leading chemotherapy.更多还原